The US Food and Drug Administration has just approved a new treatment for metastatic pancreatic cancer after a phase 3 trial ...

A glimmer of hope may be on the horizon for a ruthless cancer that former Sen. Ben Sasse (R-Neb.) once called a “definite death sentence.” An experimental treatment from Revolution Medicines helped ...

Investment in early detection will drive further progress in increasing survival rates, according to Diane Simeone, MD. Simeone spoke about the significance of these results in the context of the ...

A study co-led by UCLA found patients who received daraxonrasib, an investigational, first-in-class oral drug designed to block one of the primary drivers of pancreatic cancer, lived a median of 13.2 ...

The drug, called Rasonque, is a once-daily pill for people with pancreatic cancer who've received prior treatment, or can't ...

Please provide your email address to receive an email when new articles are posted on . Daraxonrasib nearly doubled survival vs. chemotherapy for pretreated patients with metastatic pancreatic cancer.

Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) currently recommends against routine PSA testing in this age group. The PSA ...

FDA approves Rasonque, a first-in-class targeted therapy for metastatic pancreatic cancer, offering a new treatment option for eligible patients. The U.S. Food and Drug Administration (FDA) has ...